0001209191-23-028243.txt : 20230509 0001209191-23-028243.hdr.sgml : 20230509 20230509161520 ACCESSION NUMBER: 0001209191-23-028243 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230505 FILED AS OF DATE: 20230509 DATE AS OF CHANGE: 20230509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanna Bastiano CENTRAL INDEX KEY: 0001829069 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 23902192 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-05 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001829069 Sanna Bastiano C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Cell & Genetic Therapies 1 Common Stock 2023-05-05 4 S 0 422 350.03 D 34888 D Common Stock 2023-05-08 4 S 0 2850 350.00 D 32038 D Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022. Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $350.03 (range $350.00 to $350.40). /s/ Christiana Stevenson, Attorney-in-Fact 2023-05-09